




PHARMACEUTICAL 2017

Onconova Therapeutics Inc.
Rank 220 of 292





RealRate

PHARMACEUTICAL 2017

Onconova Therapeutics Inc. Rank 220 of 292



The relative strengths and weaknesses of Onconova Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Onconova Therapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 37% points. The greatest weakness of Onconova Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 49% points.

The company's Economic Capital Ratio, given in the ranking table, is -53%, being 55% points below the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	23,069
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	10,160
Liabilities, Non-Current	0
Other Assets	12
Other Compr. Net Income	-9.0
Other Expenses	-3,974
Other Liabilities	7,946
Other Net Income	62
Other Revenues	5,546
Property and Equipment	152
Research and Development	20,071
Selling, General and Administrative Expense	9,178

Output Variable	Value in 1000 USD
Assets	23,233
Liabilities	18,106
Expenses	25,275
Revenues	5,546
Stockholders Equity	5,127
Net Income	-19,667
Comprehensive Net Income	-19,672
Economic Capital Ratio	-53%